Opinion|Videos|July 3, 2024
Topical Ruxolitinib in Vitiligo: Efficacy, Regional Approvals, and Treatment Strategies in African American Patients
Author(s)Latanya Benjamin, MD, FAAD, FAAP
Dr. Latanya Benjamin, MD, FAAD, FAAP, discusses the role of topical ruxolitinib cream in managing vitiligo and its effectiveness in a 25-year-old female patient.
Advertisement
Episodes in this series
Advertisement
Related to this article
The FDA clearance allows Edesa to expand an ongoing placebo-controlled study of the CXCL10 antibody EB06 to US sites, with topline data expected in the fourth quarter of 2027.
Dermatology clinicians at a Case-Based Roundtable in Austin, Texas, discussed real-world strategies for sequencing topical therapy, phototherapy, and ruxolitinib cream across pediatric and adult vitiligo cases.
Advertisement
Advertisement
Trending on Dermatology Times
1
Dupilumab Associated With Lower Atopic March Risk in Pediatric Atopic Dermatitis
2
Bitopertin Meets All End Points in Phase 3 APOLLO Trial for EPP
3
Social Media Mythbusters: Can Castor Oil Really Grow Hair?
4
EADV 2026 Atopic Dermatitis Highlights: Tilrekimig, RAC2 Inhibition, and Level Up Data
5